Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer

Eur J Cancer. 2022 Mar:163:177-179. doi: 10.1016/j.ejca.2021.12.025. Epub 2021 Dec 29.
No abstract available

Publication types

  • Comparative Study
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral / blood*
  • BNT162 Vaccine / administration & dosage*
  • BNT162 Vaccine / immunology
  • Biomarkers / blood
  • COVID-19 Vaccines / administration & dosage*
  • COVID-19 Vaccines / immunology
  • Humans
  • Immunity, Humoral
  • Immunization Schedule
  • Immunization, Secondary
  • Immunogenicity, Vaccine*
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Prospective Studies
  • Risk Factors
  • Time Factors
  • Treatment Outcome
  • Vaccine Efficacy

Substances

  • Antibodies, Viral
  • Biomarkers
  • COVID-19 Vaccines
  • BNT162 Vaccine

Supplementary concepts

  • COVID-19 vaccine booster shot